EP3498716A4 - Thienopyrimidine compound, preparation method therefor, pharmaceutical composition, and applications - Google Patents
Thienopyrimidine compound, preparation method therefor, pharmaceutical composition, and applications Download PDFInfo
- Publication number
- EP3498716A4 EP3498716A4 EP17838851.8A EP17838851A EP3498716A4 EP 3498716 A4 EP3498716 A4 EP 3498716A4 EP 17838851 A EP17838851 A EP 17838851A EP 3498716 A4 EP3498716 A4 EP 3498716A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- applications
- preparation
- pharmaceutical composition
- method therefor
- thienopyrimidine compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Thienopyrimidine compound Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610646949.8A CN107698603B (en) | 2016-08-09 | 2016-08-09 | Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof |
PCT/CN2017/103983 WO2018028721A1 (en) | 2016-08-09 | 2017-09-28 | Thienopyrimidine compound, preparation method therefor, pharmaceutical composition, and applications |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3498716A1 EP3498716A1 (en) | 2019-06-19 |
EP3498716A4 true EP3498716A4 (en) | 2020-03-25 |
EP3498716B1 EP3498716B1 (en) | 2024-04-17 |
Family
ID=61162766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17838851.8A Active EP3498716B1 (en) | 2016-08-09 | 2017-09-28 | Sulfonyl bearing thienopyrimidine compound, preparation method therefor, pharmaceutical composition, and application as anti-cancer agent |
Country Status (8)
Country | Link |
---|---|
US (1) | US11078213B2 (en) |
EP (1) | EP3498716B1 (en) |
JP (1) | JP6963598B2 (en) |
KR (1) | KR102429355B1 (en) |
CN (1) | CN107698603B (en) |
AU (1) | AU2017311168B2 (en) |
CA (1) | CA3033459C (en) |
WO (1) | WO2018028721A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107698603B (en) | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof |
US11279703B2 (en) * | 2016-12-01 | 2022-03-22 | Aptose Biosciences Inc. | Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof |
KR102577824B1 (en) | 2017-01-22 | 2023-09-13 | 선샤인 레이크 파르마 컴퍼니 리미티드 | Thienopyrimidine derivatives and their uses in medicine |
CN109575045B (en) * | 2017-09-28 | 2021-02-12 | 南京红云生物科技有限公司 | Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof |
WO2019154091A1 (en) * | 2018-02-07 | 2019-08-15 | 深圳市塔吉瑞生物医药有限公司 | Substituted diaminopyrimidine compound |
EP3912976A4 (en) * | 2019-01-18 | 2022-11-30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Salt of egfr inhibitor, crystal form, and preparation method therefor |
AU2020385527B2 (en) * | 2019-11-21 | 2023-04-13 | Tyk Medicines, Inc. | Compound used as EGFR kinase inhibitor and use thereof |
WO2022146027A1 (en) * | 2020-12-29 | 2022-07-07 | 주식회사 비투에스바이오 | Heteroaryl derivative compound and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009062258A1 (en) * | 2007-11-15 | 2009-05-22 | Cytopia Research Pty Ltd | N-containing heterocyclic compounds |
CN106083742A (en) * | 2016-05-31 | 2016-11-09 | 广东工业大学 | A kind of 2,4 2 amido quinazoline derivants and its preparation method and application |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1470356A1 (en) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | New thieno [3,2-d] pyrimidines and process for their preparation |
AU2002364211A1 (en) * | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
WO2006105056A2 (en) | 2005-03-28 | 2006-10-05 | Fmc Corporation | Insecticidal 2,4-diaminoquinazolines and related derivatives |
ES2562428T3 (en) | 2005-12-15 | 2016-03-04 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
JP2008013527A (en) * | 2006-07-10 | 2008-01-24 | Sankyo Co Ltd | THIENO[3,2-d]PYRIMIDINE-2,4-DIAMINE DERIVATIVE |
DK2300013T3 (en) * | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
NZ627709A (en) * | 2010-06-23 | 2014-12-24 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
EP2670401B1 (en) * | 2011-02-02 | 2015-06-10 | Novartis AG | Methods of using alk inhibitors |
KR20140011773A (en) * | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | Heterocyclic derivatives with dual inhibitory activity |
KR20140118575A (en) | 2013-03-29 | 2014-10-08 | 한미약품 주식회사 | Novel hydroxamate derivative |
CN103242341B (en) * | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | Thieno-2,4 substituted pyrimidines compounds and pharmaceutical composition thereof and application |
WO2015039612A1 (en) * | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | Compound inhibiting kinase activities of btk and/or jak3 |
JP2018522867A (en) * | 2015-06-26 | 2018-08-16 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Fused bicyclic pyrimidine derivatives and their use |
CN107698603B (en) | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof |
-
2016
- 2016-08-09 CN CN201610646949.8A patent/CN107698603B/en active Active
-
2017
- 2017-09-28 US US16/324,040 patent/US11078213B2/en active Active
- 2017-09-28 KR KR1020197006837A patent/KR102429355B1/en active IP Right Grant
- 2017-09-28 EP EP17838851.8A patent/EP3498716B1/en active Active
- 2017-09-28 JP JP2019506352A patent/JP6963598B2/en active Active
- 2017-09-28 WO PCT/CN2017/103983 patent/WO2018028721A1/en unknown
- 2017-09-28 AU AU2017311168A patent/AU2017311168B2/en active Active
- 2017-09-28 CA CA3033459A patent/CA3033459C/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009062258A1 (en) * | 2007-11-15 | 2009-05-22 | Cytopia Research Pty Ltd | N-containing heterocyclic compounds |
CN106083742A (en) * | 2016-05-31 | 2016-11-09 | 广东工业大学 | A kind of 2,4 2 amido quinazoline derivants and its preparation method and application |
Non-Patent Citations (1)
Title |
---|
JAMES T METZ ET AL: "Navigating the kinome", NATURE CHEMICAL BIOLOGY, vol. 7, no. 4, 1 April 2011 (2011-04-01), pages 200 - 202, XP055101166, ISSN: 1552-4450, DOI: 10.1038/nchembio.530 * |
Also Published As
Publication number | Publication date |
---|---|
EP3498716B1 (en) | 2024-04-17 |
EP3498716A1 (en) | 2019-06-19 |
WO2018028721A1 (en) | 2018-02-15 |
CN107698603B (en) | 2022-04-08 |
JP6963598B2 (en) | 2021-11-10 |
KR20200026782A (en) | 2020-03-11 |
CA3033459C (en) | 2023-10-24 |
JP2019524790A (en) | 2019-09-05 |
US11078213B2 (en) | 2021-08-03 |
US20200207779A2 (en) | 2020-07-02 |
AU2017311168B2 (en) | 2021-03-04 |
AU2017311168A1 (en) | 2019-02-28 |
CA3033459A1 (en) | 2018-02-15 |
CN107698603A (en) | 2018-02-16 |
KR102429355B1 (en) | 2022-08-04 |
US20190211030A1 (en) | 2019-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3436482A4 (en) | Antibodies, pharmaceutical compositions and methods | |
EP3459926A4 (en) | Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof | |
EP3312177A4 (en) | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | |
EP3259272A4 (en) | Fused-ring compounds, pharmaceutical composition and uses thereof | |
EP3290420A4 (en) | Pyrimidine pyrrole compound, preparation method therefor, pharmaceutical composition, and uses thereof | |
EP3498716A4 (en) | Thienopyrimidine compound, preparation method therefor, pharmaceutical composition, and applications | |
EP3539960A4 (en) | Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof | |
EP3299369A4 (en) | Pyrido-azaheterecydic compound and preparation method and use thereof | |
EP3398982A4 (en) | Preparation method for polymer and applications thereof | |
EP3287463A4 (en) | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | |
EP3357491A4 (en) | Pharmaceutical composition containing anionic drug, and preparation method therefor | |
EP3564253A4 (en) | Antidepressant compound and preparation method and application thereof | |
EP3438105A4 (en) | Diaryl- -lactam compound and preparation method and pharmaceutical use thereof | |
EP3406602A4 (en) | 1-sulfonamido-4-aryloxy compound, and preparation method and medicinal application thereof | |
EP3424929A4 (en) | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | |
EP3670511A4 (en) | Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition | |
EP3395366A4 (en) | Drug design method, obtained drug and application thereof | |
EP3181553A4 (en) | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | |
EP3404024A4 (en) | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | |
EP3299395A4 (en) | Oxidized -1,4-oligoglucuronic acid, and preparation method therefor and uses thereof | |
EP3626686A4 (en) | Composition for glass, glass, preparation method and application thereof | |
EP3447054A4 (en) | Compound and preparation method therefor, composition and application thereof | |
EP3647313A4 (en) | Substituted aryl ether compound, preparation method therefor, pharmaceutical composition and use thereof | |
EP3560921A4 (en) | Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof | |
EP3398615A4 (en) | Mucoadhesive pharmaceutical composition and preparation method therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190306 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200224 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/519 20060101ALI20200218BHEP Ipc: A61K 31/5377 20060101ALI20200218BHEP Ipc: A61P 35/04 20060101ALI20200218BHEP Ipc: A61P 35/02 20060101ALI20200218BHEP Ipc: A61P 35/00 20060101ALI20200218BHEP Ipc: C07D 495/04 20060101AFI20200218BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220406 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230830 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: XIAMEN UNIVERSITY |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20240119 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017081135 Country of ref document: DE |